Intelligence / Healthtech / New Clinical Trials / Polisorb Joint Stock Company
Clinicaltrial registered10 Nov 2026
Polisorb Joint Stock Company
10 Nov 2026: Trial registered · Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 10 Nov 2026
- Title
- Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Completed
- Countries
- Russia
- Country
- Russia
- Reference
- NCT07929181
- Location
- Russia
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Polisorb Joint Stock Company
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Russia
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.